Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05802173 · ClinicalTrials.gov registry record · Phase 2
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
A Phase 2 study of Alopecia, Androgenetic, sponsored by Technoderma Medicines.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
- 13
- Study locations
NCT05802173: Completed Phase 2 study of Alopecia, Androgenetic, sponsored by Technoderma Medicines.
NCT05802173 is a Phase 2 study of Alopecia, Androgenetic that has completed, run by Technoderma Medicines. The registered enrollment target is 71 participants, below the 326-participant average among 3 other Alopecia, Androgenetic trials with a reported enrollment target (78% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05802173, a Phase 2 study of Alopecia, Androgenetic, has completed, sponsored by Technoderma Medicines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
- 13
- Study locations
Study Summary
Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
Primary Outcome
Collection of non-vellus target area hair count results at week 16
Conditions Studied
Interventions
- DRUG TDM-105795, 0.0025%
- DRUG TDM-105795, 0.02%
- DRUG TDM-105795 topical vehicle solution
Study Locations (13)
Louisiana
- Site 11 - Baton Rouge
- Site 13 - New Orleans
Minnesota
- Site 10 - Minneapolis
- Site 9 - New Brighton
Tennessee
- Site 5 - Knoxville
- Site 8 - Murfreesboro
Texas
- Site 1 - Austin
- Site 6 - College Station
Arkansas
- Site 12 - North Little Rock
Illinois
- Site 4 - Rolling Meadows
Indiana
- Site 7 - Plainfield
Oregon
- Site 3 - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2024-01-29 |
| Phase | Phase 2 |
What the finished NCT05802173 record still lists
NCT05802173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 326-participant average among 3 other Alopecia, Androgenetic trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Alopecia, Androgenetic appearing as the primary indexed condition, and to 3 interventions - of which TDM-105795, 0.0025% is the first listed.
NCT05802173 lists 13 locations in 9 states (Louisiana, Minnesota, Tennessee).
Frequently Asked Questions
What is clinical trial NCT05802173 about?
NCT05802173 is a clinical study titled "Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia". Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
What is the current status of trial NCT05802173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2023-03-06. Estimated completion is 2024-01-29.
What conditions does trial NCT05802173 study?
This clinical trial studies the following conditions: Alopecia, Androgenetic.
What interventions are being tested in trial NCT05802173?
The interventions under investigation include: TDM-105795, 0.0025% (DRUG), TDM-105795, 0.02% (DRUG), TDM-105795 topical vehicle solution (DRUG).
Who is sponsoring clinical trial NCT05802173?
This trial is sponsored by Technoderma Medicines, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05802173 being conducted?
This trial has 13 study locations across Arkansas, Illinois, Indiana, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia, Androgenetic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
ACTIVE NOT RECRUITING · Phase 3
-
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI